A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children
- 1 September 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 15, 15-19
- https://doi.org/10.1097/00006454-199609009-00003
Abstract
This randomized, open label study compared the efficacy and safety of a 5-day course of once daily azithromycin to those of a 10-day course of three times daily amoxicillin/ clavulanate. One hundred sixty-nine children with confirmed acute bacterial otitis media were randomized to treatment with 10 mg/kg of azithromycin oral suspension on Day 1, followed by 5 mg/kg once daily for the next 4 days or 40 mg/kg/ day of amoxicillin/clavulanate suspension in three divided doses for 10 days. Clinical efficacy and safety were evaluated on Days 11 and 30. Analysis of evaluable patients 11 days after the start of treatment demonstrated that 87.8% of patients treated with azithromycin and 100.0% of the patients treated with amoxicillin/ clavulanate were cured or improved. Presumed bacteriologic eradication of the baseline pathogens Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes was comparable in the two groups: 87.8% in patients treated with azithromycin; and 100.0% in patients receiving amoxicillin/clavulanate. At Day 30, 82.2% of patients treated with azithromycin and 80.0% of patients treated with amoxicillin/clavulanate were cured or improved. Presumed bacteriologic eradication of the base-line pathogens was similar in the two groups: 82.2% in patients treated with azithromycin; and 81.1% in patients receiving amoxicillin/clavulanate. Relapses occurred in 5.1% of patients receiving azithromycin and 21.1% of patients taking amoxicillin/clavulanate (P = 0.047). Treatment-related side effects occurred in 3.5% of the azithromycin patients compared with 31.0% of amoxicillin/clavulanate patients (P < 0.001). Azithromycin was comparable to amoxicillin/clavulanate in achieving clinical cure or improvement and presumed eradication of baseline pathogens in pediatric patients with acute otitis media. Azithromycin was significantly better tolerated and was associated with fewer relapses than seen after amoxicillin/clavulanate therapy.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspensionAntimicrobial Agents and Chemotherapy, 1993
- Preferential concentration of azithromycin in an infected mouse thigh modelJournal of Antimicrobial Chemotherapy, 1993
- Therapeutic Considerations for Management of Otitis Media, Sinusitis, and TonsillopharyngitisPediatric Asthma, Allergy & Immunology, 1992
- Clinical toleration and safety of azithromycinThe American Journal of Medicine, 1991
- Clinical microbiology of azithromycinThe American Journal of Medicine, 1991
- Tissue-directed pharmacokineticsThe American Journal of Medicine, 1991
- Epidemiology of Otitis Media During the First Seven Years of Life in Children in Greater Boston: A Prospective, Cohort StudyThe Journal of Infectious Diseases, 1989
- In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infectionAntimicrobial Agents and Chemotherapy, 1989
- The in-vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococciJournal of Antimicrobial Chemotherapy, 1988
- Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organismsAntimicrobial Agents and Chemotherapy, 1987